Pharma & Healthcare
Global Infliximab Injection Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 569497
- Pages: 141
- Figures: 134
- Views: 7
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Infliximab Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Celltrion
Janssen Biologics
Hangzhou Bozhirui Biopharmaceuticals
Taizhou Maiboteike Pharmaceuticals
Yuxi Jiahe Biotechnology
Ayumi Pharmaceuticals
Pfizer
Nichiiko
Nippon Kayaku
AMGEN
Segment by Type
Original Drug
Generic Drug
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Infliximab Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Infliximab Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Celltrion
Janssen Biologics
Hangzhou Bozhirui Biopharmaceuticals
Taizhou Maiboteike Pharmaceuticals
Yuxi Jiahe Biotechnology
Ayumi Pharmaceuticals
Pfizer
Nichiiko
Nippon Kayaku
AMGEN
Segment by Type
Original Drug
Generic Drug
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Infliximab Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Infliximab Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Infliximab Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Original Drug
1.2.3 Generic Drug
1.3 Market Segmentation by Application
1.3.1 Global Infliximab Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Infliximab Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Infliximab Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Infliximab Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Infliximab Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Infliximab Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Infliximab Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Original Drug Market Size by Manufacturers
3.5.2 Generic Drug Market Size by Manufacturers
3.6 Global Infliximab Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Infliximab Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Infliximab Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Infliximab Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Infliximab Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Infliximab Injection Sales and Revenue by Type (2020-2031)
6.4 North America Infliximab Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Infliximab Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Infliximab Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Infliximab Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Infliximab Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Infliximab Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Infliximab Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Infliximab Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Infliximab Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Infliximab Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Infliximab Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Infliximab Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Infliximab Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Infliximab Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Celltrion
11.1.1 Celltrion Corporation Information
11.1.2 Celltrion Business Overview
11.1.3 Celltrion Infliximab Injection Product Models, Descriptions and Specifications
11.1.4 Celltrion Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Celltrion Infliximab Injection Sales by Product in 2024
11.1.6 Celltrion Infliximab Injection Sales by Application in 2024
11.1.7 Celltrion Infliximab Injection Sales by Geographic Area in 2024
11.1.8 Celltrion Infliximab Injection SWOT Analysis
11.1.9 Celltrion Recent Developments
11.2 Janssen Biologics
11.2.1 Janssen Biologics Corporation Information
11.2.2 Janssen Biologics Business Overview
11.2.3 Janssen Biologics Infliximab Injection Product Models, Descriptions and Specifications
11.2.4 Janssen Biologics Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Janssen Biologics Infliximab Injection Sales by Product in 2024
11.2.6 Janssen Biologics Infliximab Injection Sales by Application in 2024
11.2.7 Janssen Biologics Infliximab Injection Sales by Geographic Area in 2024
11.2.8 Janssen Biologics Infliximab Injection SWOT Analysis
11.2.9 Janssen Biologics Recent Developments
11.3 Hangzhou Bozhirui Biopharmaceuticals
11.3.1 Hangzhou Bozhirui Biopharmaceuticals Corporation Information
11.3.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
11.3.3 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Product Models, Descriptions and Specifications
11.3.4 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales by Product in 2024
11.3.6 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales by Application in 2024
11.3.7 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales by Geographic Area in 2024
11.3.8 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection SWOT Analysis
11.3.9 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
11.4 Taizhou Maiboteike Pharmaceuticals
11.4.1 Taizhou Maiboteike Pharmaceuticals Corporation Information
11.4.2 Taizhou Maiboteike Pharmaceuticals Business Overview
11.4.3 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Product Models, Descriptions and Specifications
11.4.4 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales by Product in 2024
11.4.6 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales by Application in 2024
11.4.7 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales by Geographic Area in 2024
11.4.8 Taizhou Maiboteike Pharmaceuticals Infliximab Injection SWOT Analysis
11.4.9 Taizhou Maiboteike Pharmaceuticals Recent Developments
11.5 Yuxi Jiahe Biotechnology
11.5.1 Yuxi Jiahe Biotechnology Corporation Information
11.5.2 Yuxi Jiahe Biotechnology Business Overview
11.5.3 Yuxi Jiahe Biotechnology Infliximab Injection Product Models, Descriptions and Specifications
11.5.4 Yuxi Jiahe Biotechnology Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Yuxi Jiahe Biotechnology Infliximab Injection Sales by Product in 2024
11.5.6 Yuxi Jiahe Biotechnology Infliximab Injection Sales by Application in 2024
11.5.7 Yuxi Jiahe Biotechnology Infliximab Injection Sales by Geographic Area in 2024
11.5.8 Yuxi Jiahe Biotechnology Infliximab Injection SWOT Analysis
11.5.9 Yuxi Jiahe Biotechnology Recent Developments
11.6 Ayumi Pharmaceuticals
11.6.1 Ayumi Pharmaceuticals Corporation Information
11.6.2 Ayumi Pharmaceuticals Business Overview
11.6.3 Ayumi Pharmaceuticals Infliximab Injection Product Models, Descriptions and Specifications
11.6.4 Ayumi Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Ayumi Pharmaceuticals Recent Developments
11.7 Pfizer
11.7.1 Pfizer Corporation Information
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Infliximab Injection Product Models, Descriptions and Specifications
11.7.4 Pfizer Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Pfizer Recent Developments
11.8 Nichiiko
11.8.1 Nichiiko Corporation Information
11.8.2 Nichiiko Business Overview
11.8.3 Nichiiko Infliximab Injection Product Models, Descriptions and Specifications
11.8.4 Nichiiko Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Nichiiko Recent Developments
11.9 Nippon Kayaku
11.9.1 Nippon Kayaku Corporation Information
11.9.2 Nippon Kayaku Business Overview
11.9.3 Nippon Kayaku Infliximab Injection Product Models, Descriptions and Specifications
11.9.4 Nippon Kayaku Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Nippon Kayaku Recent Developments
11.10 AMGEN
11.10.1 AMGEN Corporation Information
11.10.2 AMGEN Business Overview
11.10.3 AMGEN Infliximab Injection Product Models, Descriptions and Specifications
11.10.4 AMGEN Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 AMGEN Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Infliximab Injection Industry Chain
12.2 Infliximab Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Infliximab Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Infliximab Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Infliximab Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Infliximab Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Infliximab Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Infliximab Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Original Drug
1.2.3 Generic Drug
1.3 Market Segmentation by Application
1.3.1 Global Infliximab Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Infliximab Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Infliximab Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Infliximab Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Infliximab Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Infliximab Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Infliximab Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Original Drug Market Size by Manufacturers
3.5.2 Generic Drug Market Size by Manufacturers
3.6 Global Infliximab Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Infliximab Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Infliximab Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Infliximab Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Infliximab Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Infliximab Injection Sales and Revenue by Type (2020-2031)
6.4 North America Infliximab Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Infliximab Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Infliximab Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Infliximab Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Infliximab Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Infliximab Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Infliximab Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Infliximab Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Infliximab Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Infliximab Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Infliximab Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Infliximab Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Infliximab Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Infliximab Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Celltrion
11.1.1 Celltrion Corporation Information
11.1.2 Celltrion Business Overview
11.1.3 Celltrion Infliximab Injection Product Models, Descriptions and Specifications
11.1.4 Celltrion Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Celltrion Infliximab Injection Sales by Product in 2024
11.1.6 Celltrion Infliximab Injection Sales by Application in 2024
11.1.7 Celltrion Infliximab Injection Sales by Geographic Area in 2024
11.1.8 Celltrion Infliximab Injection SWOT Analysis
11.1.9 Celltrion Recent Developments
11.2 Janssen Biologics
11.2.1 Janssen Biologics Corporation Information
11.2.2 Janssen Biologics Business Overview
11.2.3 Janssen Biologics Infliximab Injection Product Models, Descriptions and Specifications
11.2.4 Janssen Biologics Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Janssen Biologics Infliximab Injection Sales by Product in 2024
11.2.6 Janssen Biologics Infliximab Injection Sales by Application in 2024
11.2.7 Janssen Biologics Infliximab Injection Sales by Geographic Area in 2024
11.2.8 Janssen Biologics Infliximab Injection SWOT Analysis
11.2.9 Janssen Biologics Recent Developments
11.3 Hangzhou Bozhirui Biopharmaceuticals
11.3.1 Hangzhou Bozhirui Biopharmaceuticals Corporation Information
11.3.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
11.3.3 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Product Models, Descriptions and Specifications
11.3.4 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales by Product in 2024
11.3.6 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales by Application in 2024
11.3.7 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales by Geographic Area in 2024
11.3.8 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection SWOT Analysis
11.3.9 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
11.4 Taizhou Maiboteike Pharmaceuticals
11.4.1 Taizhou Maiboteike Pharmaceuticals Corporation Information
11.4.2 Taizhou Maiboteike Pharmaceuticals Business Overview
11.4.3 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Product Models, Descriptions and Specifications
11.4.4 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales by Product in 2024
11.4.6 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales by Application in 2024
11.4.7 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales by Geographic Area in 2024
11.4.8 Taizhou Maiboteike Pharmaceuticals Infliximab Injection SWOT Analysis
11.4.9 Taizhou Maiboteike Pharmaceuticals Recent Developments
11.5 Yuxi Jiahe Biotechnology
11.5.1 Yuxi Jiahe Biotechnology Corporation Information
11.5.2 Yuxi Jiahe Biotechnology Business Overview
11.5.3 Yuxi Jiahe Biotechnology Infliximab Injection Product Models, Descriptions and Specifications
11.5.4 Yuxi Jiahe Biotechnology Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Yuxi Jiahe Biotechnology Infliximab Injection Sales by Product in 2024
11.5.6 Yuxi Jiahe Biotechnology Infliximab Injection Sales by Application in 2024
11.5.7 Yuxi Jiahe Biotechnology Infliximab Injection Sales by Geographic Area in 2024
11.5.8 Yuxi Jiahe Biotechnology Infliximab Injection SWOT Analysis
11.5.9 Yuxi Jiahe Biotechnology Recent Developments
11.6 Ayumi Pharmaceuticals
11.6.1 Ayumi Pharmaceuticals Corporation Information
11.6.2 Ayumi Pharmaceuticals Business Overview
11.6.3 Ayumi Pharmaceuticals Infliximab Injection Product Models, Descriptions and Specifications
11.6.4 Ayumi Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Ayumi Pharmaceuticals Recent Developments
11.7 Pfizer
11.7.1 Pfizer Corporation Information
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Infliximab Injection Product Models, Descriptions and Specifications
11.7.4 Pfizer Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Pfizer Recent Developments
11.8 Nichiiko
11.8.1 Nichiiko Corporation Information
11.8.2 Nichiiko Business Overview
11.8.3 Nichiiko Infliximab Injection Product Models, Descriptions and Specifications
11.8.4 Nichiiko Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Nichiiko Recent Developments
11.9 Nippon Kayaku
11.9.1 Nippon Kayaku Corporation Information
11.9.2 Nippon Kayaku Business Overview
11.9.3 Nippon Kayaku Infliximab Injection Product Models, Descriptions and Specifications
11.9.4 Nippon Kayaku Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Nippon Kayaku Recent Developments
11.10 AMGEN
11.10.1 AMGEN Corporation Information
11.10.2 AMGEN Business Overview
11.10.3 AMGEN Infliximab Injection Product Models, Descriptions and Specifications
11.10.4 AMGEN Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 AMGEN Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Infliximab Injection Industry Chain
12.2 Infliximab Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Infliximab Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Infliximab Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Infliximab Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Infliximab Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Infliximab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Infliximab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Infliximab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Infliximab Injection Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Infliximab Injection Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Infliximab Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Infliximab Injection Sales by Region (2020-2025) & (K Units)
Table 8. Global Infliximab Injection Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Infliximab Injection Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Infliximab Injection Sales Share by Manufacturers (2020-2025)
Table 12. Global Infliximab Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Infliximab Injection Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Infliximab Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infliximab Injection as of 2024)
Table 16. Global Infliximab Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Infliximab Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Infliximab Injection Manufacturing Base and Headquarters
Table 19. Global Infliximab Injection Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Infliximab Injection Sales by Type (2020-2025) & (K Units)
Table 23. Global Infliximab Injection Sales by Type (2026-2031) & (K Units)
Table 24. Global Infliximab Injection Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Infliximab Injection Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Infliximab Injection ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Infliximab Injection Sales by Application (2020-2025) & (K Units)
Table 29. Global Infliximab Injection Sales by Application (2026-2031) & (K Units)
Table 30. Infliximab Injection High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Infliximab Injection Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Infliximab Injection Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Infliximab Injection ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Infliximab Injection Growth Accelerators and Market Barriers
Table 37. North America Infliximab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Infliximab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Infliximab Injection Growth Accelerators and Market Barriers
Table 40. Europe Infliximab Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Infliximab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Infliximab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Infliximab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Infliximab Injection Growth Accelerators and Market Barriers
Table 45. Southeast Asia Infliximab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Infliximab Injection Investment Opportunities and Key Challenges
Table 47. Central and South America Infliximab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Infliximab Injection Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Infliximab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Celltrion Corporation Information
Table 51. Celltrion Description and Major Businesses
Table 52. Celltrion Product Models, Descriptions and Specifications
Table 53. Celltrion Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Celltrion Sales Value Proportion by Product in 2024
Table 55. Celltrion Sales Value Proportion by Application in 2024
Table 56. Celltrion Sales Value Proportion by Geographic Area in 2024
Table 57. Celltrion Infliximab Injection SWOT Analysis
Table 58. Celltrion Recent Developments
Table 59. Janssen Biologics Corporation Information
Table 60. Janssen Biologics Description and Major Businesses
Table 61. Janssen Biologics Product Models, Descriptions and Specifications
Table 62. Janssen Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Janssen Biologics Sales Value Proportion by Product in 2024
Table 64. Janssen Biologics Sales Value Proportion by Application in 2024
Table 65. Janssen Biologics Sales Value Proportion by Geographic Area in 2024
Table 66. Janssen Biologics Infliximab Injection SWOT Analysis
Table 67. Janssen Biologics Recent Developments
Table 68. Hangzhou Bozhirui Biopharmaceuticals Corporation Information
Table 69. Hangzhou Bozhirui Biopharmaceuticals Description and Major Businesses
Table 70. Hangzhou Bozhirui Biopharmaceuticals Product Models, Descriptions and Specifications
Table 71. Hangzhou Bozhirui Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Hangzhou Bozhirui Biopharmaceuticals Sales Value Proportion by Product in 2024
Table 73. Hangzhou Bozhirui Biopharmaceuticals Sales Value Proportion by Application in 2024
Table 74. Hangzhou Bozhirui Biopharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 75. Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection SWOT Analysis
Table 76. Hangzhou Bozhirui Biopharmaceuticals Recent Developments
Table 77. Taizhou Maiboteike Pharmaceuticals Corporation Information
Table 78. Taizhou Maiboteike Pharmaceuticals Description and Major Businesses
Table 79. Taizhou Maiboteike Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Taizhou Maiboteike Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Taizhou Maiboteike Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Taizhou Maiboteike Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Taizhou Maiboteike Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Taizhou Maiboteike Pharmaceuticals Infliximab Injection SWOT Analysis
Table 85. Taizhou Maiboteike Pharmaceuticals Recent Developments
Table 86. Yuxi Jiahe Biotechnology Corporation Information
Table 87. Yuxi Jiahe Biotechnology Description and Major Businesses
Table 88. Yuxi Jiahe Biotechnology Product Models, Descriptions and Specifications
Table 89. Yuxi Jiahe Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Yuxi Jiahe Biotechnology Sales Value Proportion by Product in 2024
Table 91. Yuxi Jiahe Biotechnology Sales Value Proportion by Application in 2024
Table 92. Yuxi Jiahe Biotechnology Sales Value Proportion by Geographic Area in 2024
Table 93. Yuxi Jiahe Biotechnology Infliximab Injection SWOT Analysis
Table 94. Yuxi Jiahe Biotechnology Recent Developments
Table 95. Ayumi Pharmaceuticals Corporation Information
Table 96. Ayumi Pharmaceuticals Description and Major Businesses
Table 97. Ayumi Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Ayumi Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Ayumi Pharmaceuticals Recent Developments
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Major Businesses
Table 102. Pfizer Product Models, Descriptions and Specifications
Table 103. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Pfizer Recent Developments
Table 105. Nichiiko Corporation Information
Table 106. Nichiiko Description and Major Businesses
Table 107. Nichiiko Product Models, Descriptions and Specifications
Table 108. Nichiiko Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Nichiiko Recent Developments
Table 110. Nippon Kayaku Corporation Information
Table 111. Nippon Kayaku Description and Major Businesses
Table 112. Nippon Kayaku Product Models, Descriptions and Specifications
Table 113. Nippon Kayaku Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Nippon Kayaku Recent Developments
Table 115. AMGEN Corporation Information
Table 116. AMGEN Description and Major Businesses
Table 117. AMGEN Product Models, Descriptions and Specifications
Table 118. AMGEN Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. AMGEN Recent Developments
Table 120. Key Raw Materials Distribution
Table 121. Raw Materials Key Suppliers
Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 123. Milestones in Production Technology Evolution
Table 124. Distributors List
Table 125. Market Trends and Market Evolution
Table 126. Market Drivers and Opportunities
Table 127. Market Challenges, Risks, and Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Infliximab Injection Product Picture
Figure 2. Global Infliximab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Original Drug Product Picture
Figure 4. Generic Drug Product Picture
Figure 5. Global Infliximab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Other
Figure 9. Infliximab Injection Report Years Considered
Figure 10. Global Infliximab Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 12. Global Infliximab Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Infliximab Injection Revenue Market Share by Region (2020-2031)
Figure 14. Global Infliximab Injection Sales (2020-2031) & (K Units)
Figure 15. Global Infliximab Injection Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Infliximab Injection Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Infliximab Injection Sales Volume Market Share in 2024
Figure 18. Global Infliximab Injection Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Original Drug Revenue Market Share by Manufacturer in 2024
Figure 21. Generic Drug Revenue Market Share by Manufacturer in 2024
Figure 22. Global Infliximab Injection Sales Market Share by Type (2020-2031)
Figure 23. Global Infliximab Injection Revenue Market Share by Type (2020-2031)
Figure 24. Global Infliximab Injection Sales Market Share by Application (2020-2031)
Figure 25. Global Infliximab Injection Revenue Market Share by Application (2020-2031)
Figure 26. North America Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 27. North America Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 29. North America Infliximab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Infliximab Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 39. Europe Infliximab Injection Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Infliximab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 44. France Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Infliximab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Infliximab Injection Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 59. India Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Infliximab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Infliximab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Infliximab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Infliximab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 80. Infliximab Injection Industry Chain Mapping
Figure 81. Regional Infliximab Injection Manufacturing Base Distribution (%)
Figure 82. Global Infliximab Injection Production Market Share by Region (2020-2031)
Figure 83. Infliximab Injection Production Process
Figure 84. Regional Infliximab Injection Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Table 1. Global Infliximab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Infliximab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Infliximab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Infliximab Injection Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Infliximab Injection Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Infliximab Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Infliximab Injection Sales by Region (2020-2025) & (K Units)
Table 8. Global Infliximab Injection Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Infliximab Injection Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Infliximab Injection Sales Share by Manufacturers (2020-2025)
Table 12. Global Infliximab Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Infliximab Injection Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Infliximab Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infliximab Injection as of 2024)
Table 16. Global Infliximab Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Infliximab Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Infliximab Injection Manufacturing Base and Headquarters
Table 19. Global Infliximab Injection Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Infliximab Injection Sales by Type (2020-2025) & (K Units)
Table 23. Global Infliximab Injection Sales by Type (2026-2031) & (K Units)
Table 24. Global Infliximab Injection Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Infliximab Injection Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Infliximab Injection ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Infliximab Injection Sales by Application (2020-2025) & (K Units)
Table 29. Global Infliximab Injection Sales by Application (2026-2031) & (K Units)
Table 30. Infliximab Injection High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Infliximab Injection Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Infliximab Injection Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Infliximab Injection ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Infliximab Injection Growth Accelerators and Market Barriers
Table 37. North America Infliximab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Infliximab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Infliximab Injection Growth Accelerators and Market Barriers
Table 40. Europe Infliximab Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Infliximab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Infliximab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Infliximab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Infliximab Injection Growth Accelerators and Market Barriers
Table 45. Southeast Asia Infliximab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Infliximab Injection Investment Opportunities and Key Challenges
Table 47. Central and South America Infliximab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Infliximab Injection Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Infliximab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Celltrion Corporation Information
Table 51. Celltrion Description and Major Businesses
Table 52. Celltrion Product Models, Descriptions and Specifications
Table 53. Celltrion Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Celltrion Sales Value Proportion by Product in 2024
Table 55. Celltrion Sales Value Proportion by Application in 2024
Table 56. Celltrion Sales Value Proportion by Geographic Area in 2024
Table 57. Celltrion Infliximab Injection SWOT Analysis
Table 58. Celltrion Recent Developments
Table 59. Janssen Biologics Corporation Information
Table 60. Janssen Biologics Description and Major Businesses
Table 61. Janssen Biologics Product Models, Descriptions and Specifications
Table 62. Janssen Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Janssen Biologics Sales Value Proportion by Product in 2024
Table 64. Janssen Biologics Sales Value Proportion by Application in 2024
Table 65. Janssen Biologics Sales Value Proportion by Geographic Area in 2024
Table 66. Janssen Biologics Infliximab Injection SWOT Analysis
Table 67. Janssen Biologics Recent Developments
Table 68. Hangzhou Bozhirui Biopharmaceuticals Corporation Information
Table 69. Hangzhou Bozhirui Biopharmaceuticals Description and Major Businesses
Table 70. Hangzhou Bozhirui Biopharmaceuticals Product Models, Descriptions and Specifications
Table 71. Hangzhou Bozhirui Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Hangzhou Bozhirui Biopharmaceuticals Sales Value Proportion by Product in 2024
Table 73. Hangzhou Bozhirui Biopharmaceuticals Sales Value Proportion by Application in 2024
Table 74. Hangzhou Bozhirui Biopharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 75. Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection SWOT Analysis
Table 76. Hangzhou Bozhirui Biopharmaceuticals Recent Developments
Table 77. Taizhou Maiboteike Pharmaceuticals Corporation Information
Table 78. Taizhou Maiboteike Pharmaceuticals Description and Major Businesses
Table 79. Taizhou Maiboteike Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Taizhou Maiboteike Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Taizhou Maiboteike Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Taizhou Maiboteike Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Taizhou Maiboteike Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Taizhou Maiboteike Pharmaceuticals Infliximab Injection SWOT Analysis
Table 85. Taizhou Maiboteike Pharmaceuticals Recent Developments
Table 86. Yuxi Jiahe Biotechnology Corporation Information
Table 87. Yuxi Jiahe Biotechnology Description and Major Businesses
Table 88. Yuxi Jiahe Biotechnology Product Models, Descriptions and Specifications
Table 89. Yuxi Jiahe Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Yuxi Jiahe Biotechnology Sales Value Proportion by Product in 2024
Table 91. Yuxi Jiahe Biotechnology Sales Value Proportion by Application in 2024
Table 92. Yuxi Jiahe Biotechnology Sales Value Proportion by Geographic Area in 2024
Table 93. Yuxi Jiahe Biotechnology Infliximab Injection SWOT Analysis
Table 94. Yuxi Jiahe Biotechnology Recent Developments
Table 95. Ayumi Pharmaceuticals Corporation Information
Table 96. Ayumi Pharmaceuticals Description and Major Businesses
Table 97. Ayumi Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Ayumi Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Ayumi Pharmaceuticals Recent Developments
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Major Businesses
Table 102. Pfizer Product Models, Descriptions and Specifications
Table 103. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Pfizer Recent Developments
Table 105. Nichiiko Corporation Information
Table 106. Nichiiko Description and Major Businesses
Table 107. Nichiiko Product Models, Descriptions and Specifications
Table 108. Nichiiko Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Nichiiko Recent Developments
Table 110. Nippon Kayaku Corporation Information
Table 111. Nippon Kayaku Description and Major Businesses
Table 112. Nippon Kayaku Product Models, Descriptions and Specifications
Table 113. Nippon Kayaku Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Nippon Kayaku Recent Developments
Table 115. AMGEN Corporation Information
Table 116. AMGEN Description and Major Businesses
Table 117. AMGEN Product Models, Descriptions and Specifications
Table 118. AMGEN Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. AMGEN Recent Developments
Table 120. Key Raw Materials Distribution
Table 121. Raw Materials Key Suppliers
Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 123. Milestones in Production Technology Evolution
Table 124. Distributors List
Table 125. Market Trends and Market Evolution
Table 126. Market Drivers and Opportunities
Table 127. Market Challenges, Risks, and Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Infliximab Injection Product Picture
Figure 2. Global Infliximab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Original Drug Product Picture
Figure 4. Generic Drug Product Picture
Figure 5. Global Infliximab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Other
Figure 9. Infliximab Injection Report Years Considered
Figure 10. Global Infliximab Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 12. Global Infliximab Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Infliximab Injection Revenue Market Share by Region (2020-2031)
Figure 14. Global Infliximab Injection Sales (2020-2031) & (K Units)
Figure 15. Global Infliximab Injection Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Infliximab Injection Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Infliximab Injection Sales Volume Market Share in 2024
Figure 18. Global Infliximab Injection Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Original Drug Revenue Market Share by Manufacturer in 2024
Figure 21. Generic Drug Revenue Market Share by Manufacturer in 2024
Figure 22. Global Infliximab Injection Sales Market Share by Type (2020-2031)
Figure 23. Global Infliximab Injection Revenue Market Share by Type (2020-2031)
Figure 24. Global Infliximab Injection Sales Market Share by Application (2020-2031)
Figure 25. Global Infliximab Injection Revenue Market Share by Application (2020-2031)
Figure 26. North America Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 27. North America Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 29. North America Infliximab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Infliximab Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 39. Europe Infliximab Injection Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Infliximab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 44. France Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Infliximab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Infliximab Injection Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 59. India Infliximab Injection Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Infliximab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Infliximab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Infliximab Injection Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Infliximab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Infliximab Injection Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Infliximab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Infliximab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Infliximab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Infliximab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Infliximab Injection Revenue (2020-2025) & (US$ Million)
Figure 80. Infliximab Injection Industry Chain Mapping
Figure 81. Regional Infliximab Injection Manufacturing Base Distribution (%)
Figure 82. Global Infliximab Injection Production Market Share by Region (2020-2031)
Figure 83. Infliximab Injection Production Process
Figure 84. Regional Infliximab Injection Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232